GAD Drug Development Has Stalled for 16 Years. iNGENu CRO Is Building the Trial Framework to Change That.

image via Medical Daily

March 19, 2026, 3:30 AM

• •No new GAD treatment has been approved by the FDA since 2009.
• •GAD trials face challenges from complex neurobiology and a high placebo effect.
• •Successful trial design requires precision in patient selection, appropriate outcome measures, and management of the placebo effect.
• •The Australian clinical trial infrastructure provides a cost-effective pathway to FDA approval for biotech firms.

Generalized Anxiety Disorder (GAD) presents significant challenges for drug development, with the last FDA approval for a new treatment dating back to 2009. The complexity of GAD's neurobiology, the high placebo effect in trials, and the FDA's rigorous standards contribute to the difficulty. However, the high prevalence of GAD and limitations of existing treatments create a substantial market opportunity for biotech firms. Success hinges on precise trial design, addressing the historical pitfalls, and embracing innovative approaches.

Read original article